{"corpus_id":25407135,"paper_sha":"7d66db10695c406aaeba4f430732c0734bee7217","doi":"10.1200/JCO.2006.09.6305","arxiv_id":null,"pmid":17442997,"pmcid":null,"mag_id":2125447919,"dblp_id":null,"acl_id":null,"title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.","year":2007,"publication_date":"2007-04-20","venue":"Journal of Clinical Oncology","journal":{"name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pages":"\n          1539-44\n        ","volume":"25 12"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial, Phase III","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, N.I.H., Extramural"],"s2_fields_of_study":["Medicine"],"reference_count":26,"citation_count":2341,"influential_citation_count":113,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Aged, 80 and over","mj":false,"ui":"D000369"},{"d":"Antibodies, Monoclonal","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D000911"},{"d":"Antibodies, Monoclonal, Humanized","mj":false,"ui":"D061067"},{"d":"Antineoplastic Combined Chemotherapy Protocols","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000971"},{"d":"Bevacizumab","mj":false,"ui":"D000068258"},{"d":"Colorectal Neoplasms","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"mortality","mj":true,"ui":"Q000401"},{"q":"pathology","mj":false,"ui":"Q000473"}],"ui":"D015179"},{"d":"Disease Progression","mj":false,"ui":"D018450"},{"d":"Dose-Response Relationship, Drug","mj":false,"ui":"D004305"},{"d":"Drug Administration Schedule","mj":false,"ui":"D004334"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Fluorouracil","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D005472"},{"d":"Follow-Up Studies","mj":false,"ui":"D005500"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Leucovorin","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D002955"},{"d":"Liver Neoplasms","mj":false,"qs":[{"q":"secondary","mj":false,"ui":"Q000556"}],"ui":"D008113"},{"d":"Lung Neoplasms","mj":false,"qs":[{"q":"secondary","mj":false,"ui":"Q000556"}],"ui":"D008175"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Maximum Tolerated Dose","mj":false,"ui":"D020714"},{"d":"Medical Oncology","mj":false,"ui":"D008495"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Neoplasm Staging","mj":false,"ui":"D009367"},{"d":"Organoplatinum Compounds","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D009944"},{"d":"Oxaliplatin","mj":false,"ui":"D000077150"},{"d":"Probability","mj":false,"ui":"D011336"},{"d":"Risk Assessment","mj":false,"ui":"D018570"},{"d":"Salvage Therapy","mj":true,"ui":"D016879"},{"d":"Single-Blind Method","mj":false,"ui":"D016037"},{"d":"Survival Analysis","mj":false,"ui":"D016019"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"},{"d":"United States","mj":false,"ui":"D014481"}],"chemicals":[{"n":"Antibodies, Monoclonal","ui":"D000911","reg":"0"},{"n":"Antibodies, Monoclonal, Humanized","ui":"D061067","reg":"0"},{"n":"Organoplatinum Compounds","ui":"D009944","reg":"0"},{"n":"Oxaliplatin","ui":"D000077150","reg":"04ZR38536J"},{"n":"Bevacizumab","ui":"D000068258","reg":"2S9ZZM9Q9V"},{"n":"Leucovorin","ui":"D002955","reg":"Q573I9DVLP"},{"n":"Fluorouracil","ui":"D005472","reg":"U3P01618RT"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.09.6305?role=tab","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/7d66db10695c406aaeba4f430732c0734bee7217","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"PURPOSE: Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer. PATIENTS AND METHODS: Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone. The primary end point was overall survival, with additional determinations of progression-free survival, response, and toxicity. RESULTS: The median duration of survival for the group treated with FOLFOX4 and bevacizumab was 12.9 months compared with 10.8 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for death = 0.75; P = .0011), and 10.2 months for those treated with bevacizumab alone. The median progression-free survival for the group treated with FOLFOX4 in combination with bevacizumab was 7.3 months, compared with 4.7 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for progression = 0.61; P < .0001), and 2.7 months for those treated with bevacizumab alone. The corresponding overall response rates were 22.7%, 8.6%, and 3.3%, respectively (P < .0001 for FOLFOX4 with bevacizumab v FOLFOX4 comparison). Bevacizumab was associated with hypertension, bleeding, and vomiting. CONCLUSION: The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal.","claims":[{"public_id":"cl_4e224afb12399621dc051e6b46b2a6ca","status":"active","text":"Adding bevacizumab to FOLFOX4 improves the overall response rate compared with FOLFOX4 alone in previously treated metastatic colorectal cancer.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4e224afb12399621dc051e6b46b2a6ca"},{"public_id":"cl_29c8815ef5a5470ef8afa05aafdd1c17","status":"active","text":"Adding bevacizumab to FOLFOX4 increases overall survival in previously treated metastatic colorectal cancer.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_29c8815ef5a5470ef8afa05aafdd1c17"},{"public_id":"cl_ba2933a5697d635248d412396335d117","status":"active","text":"Adding bevacizumab to FOLFOX4 increases progression-free survival compared with FOLFOX4 alone in previously treated metastatic colorectal cancer.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ba2933a5697d635248d412396335d117"},{"public_id":"cl_906d2bcc5e73ed37217c64cca8f54f3f","status":"active","text":"Bevacizumab is associated with hypertension, bleeding, and vomiting.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_906d2bcc5e73ed37217c64cca8f54f3f"}],"concepts":[{"public_id":"co_4b62932db0bdbae267518ef9d442edda","status":"active","name":"vomiting","description":"Emesis reported as a treatment-associated adverse event.","types":["adverse event","toxicity"],"aliases":["emesis"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4b62932db0bdbae267518ef9d442edda"},{"public_id":"co_54e75a4a6f128b9f4fa2baef115ed7c9","status":"active","name":"overall response rate","description":"The proportion of patients whose tumors show a predefined response to treatment.","types":["outcome measure","endpoint"],"aliases":["response rate","ORR"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_54e75a4a6f128b9f4fa2baef115ed7c9"},{"public_id":"co_5b081104717ef704f1bf2f36c96bc403","status":"active","name":"FOLFOX4","description":"An oxaliplatin-based chemotherapy regimen combining oxaliplatin, fluorouracil, and leucovorin.","types":["chemotherapy regimen","treatment"],"aliases":["oxaliplatin, fluorouracil, and leucovorin"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5b081104717ef704f1bf2f36c96bc403"},{"public_id":"co_a2e1fa121ceae0bd5f600ef9173b8f2b","status":"active","name":"bleeding","description":"Hemorrhagic adverse event reported in association with treatment.","types":["adverse event","toxicity"],"aliases":["hemorrhage"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a2e1fa121ceae0bd5f600ef9173b8f2b"},{"public_id":"co_b9eb188402e3eba0e5f233cc654c2ab7","status":"active","name":"hypertension","description":"Elevated blood pressure reported as a treatment-associated adverse event.","types":["adverse event","toxicity"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b9eb188402e3eba0e5f233cc654c2ab7"},{"public_id":"co_bff3d4453c16bca060cadefac9a1070d","status":"active","name":"bevacizumab","description":"A monoclonal antibody that inhibits vascular endothelial growth factor and is used as an antiangiogenic cancer therapy.","types":["drug","therapeutic agent"],"aliases":["Avastin"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bff3d4453c16bca060cadefac9a1070d"},{"public_id":"co_ed2a09465ddad24a30df2f762e86ecef","status":"active","name":"previously treated metastatic colorectal cancer","description":"Metastatic colorectal cancer in patients who have already received prior systemic therapy.","types":["condition","patient population"],"aliases":["previously treated metastatic colorectal"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ed2a09465ddad24a30df2f762e86ecef"},{"public_id":"co_ef712e10a2890639b2c3eed55c13b9a5","status":"active","name":"overall survival","description":"The length of time from treatment start or randomization until death from any cause.","types":["outcome measure","endpoint"],"aliases":["OS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ef712e10a2890639b2c3eed55c13b9a5"},{"public_id":"co_f1a0f5f7713d2025b1f42be9a37aabfd","status":"active","name":"progression-free survival","description":"The length of time during and after treatment that a patient lives without disease progression.","types":["outcome measure","endpoint"],"aliases":["PFS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f1a0f5f7713d2025b1f42be9a37aabfd"}],"external_ids":{"DOI":"10.1200/JCO.2006.09.6305","ArXiv":null,"PubMed":17442997,"PubMedCentral":null,"MAG":2125447919,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.09.6305?role=tab","landing_url":"https://www.semanticscholar.org/paper/7d66db10695c406aaeba4f430732c0734bee7217","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632183,"paper_uid":"af2eb917-2126-4df3-b52e-3d3cc508bb04","canonical_identity":{"paper_id":632183,"paper_uid":"af2eb917-2126-4df3-b52e-3d3cc508bb04","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/25407135"}